Loading data for CTMX — first visit, this takes a few seconds.
CytomX Therapeutics Inc. (CTMX)
NasdaqGS: CTMX
· Real-Time Price · USD
3.33
+0.04 (1.22%)
At close: Aug 21, 2026, 8:00 PM
3.28
+0.00%
After-hours: 7:30 PM
The price, the headline numbers and the latest news, in one place.
CytomX Therapeutics Inc. (CTMX) Stock Price, Analysis & Data
1.22% (1D)
No data available
| Bid | 3.33 |
| Market Cap | 714.71M |
| Revenue (ttm) | 18.3M |
| Net Income (ttm) | -82.66M |
| 2.14 | |
| -0.57 | |
| n/a | |
| -6.93 | |
| P/B (ttm) | 2.37 |
| P/S (ttm) | 39.05 |
| Earnings Date | n/a |
| Ask | 3.4 |
| Volume | 1,039,073 |
| Avg. Volume (20D) | 3,972,095 |
| Open | 3.31 |
| Previous Close | 3.29 |
| Day's Range | 3.31 - 3.42 |
| 52-Week Range | 1.90 - 8.21 |
| Analyst | n/a |
| Price Target | n/a |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About CTMX
CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company that focuses on developing potent biologics designed to treat tumor microenvironment. The company utilizes conditional activation platform technology for oncology biologics research and development comprising the validation of targets for antibody-drug conjugates (ADCs), opening therapeutic window for novel T-cell engagers (TCEs) targeting solid tumors, and increa...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 8, 2015
Employees 69
Stock Exchange NasdaqGS
Ticker Symbol CTMX
Website https://www.cytomx.com
Financial Performance
In 2025, CytomX Therapeutics's revenue was 76.2M, a decrease of -44.82% compared to the previous year's 138.1M. Earnings were -17.37M, a decrease of -154.5%.
Financial Statements